North China Pharmaceutical expands product portfolio with approvals

North China Pharmaceutical (SSE:600812) announced that its subsidiary, Huabei Pharmaceutical Huasheng Co., Ltd., has received approval from the National Medical Products Administration for its Polymyxin B Sulfate chemical API. Concurrently, its fully-owned subsidiary, North China Pharmaceutical Hebei Huamin Pharmaceutical Co., Ltd., obtained a drug registration certificate for Ceftazidime and Avibactam Sodium for Injection (2.5g). Polymyxin B Sulfate is indicated for acute infections caused by susceptible strains of Pseudomonas aeruginosa. Ceftazidime and Avibactam Sodium for Injection is approved for treating infections caused by gram-negative bacteria, including cephalosporin-resistant strains.